Nexavar given green light to treat thyroid cancer

30 May 2014

Nexavar, the drug developed by Bayer and Amgen unit Onyx Pharmaceuticals to treat advanced kidney and liver cancers, has been approved for the treatment of the most common form of thyroid cancer.

The European Commission has given the green light for Nexavar (otherwise known as sorafenib) to be used to treat metastatic differentiated thyroid carcinoma that is refractory to radioactive iodine treatment, reports PharmaTimes.

The approval is based upon data from a trial showing that the oral multi-kinase inhibitor extended progression-free survival by 41% compared to placebo (10.8 months versus 5.8 months).

"We are proud to extend this proven treatment option to even more people in need," said Joerg Moeller, head of global development at Bayer HealthCare.

The drug was approved for the thyroid cancer indication by the US Food and Drug Administration in November 2013. There are more than 298,000 new cases of thyroid cancer annually and nearly 40,000 people die from the disease worldwide each year.

Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.